Physician profile
Shelly C Bray
NPI 1902824162
$4,027.73
in general payments reported to CMS, 2019-2025
33 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $664 · 2021: $707 · 2022: $448 · 2023: $496 · 2024: $476 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $718.14 | 2019-2025 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $669.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $378.56 | 2019-2022 | |
| Lilly USA, LLC | $296.69 | 2019-2024 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $240.08 | 2019-2022 | |
| Pfizer INC. | $221.95 | 2019-2022 | |
| Abbvie INC. | $182.73 | 2021-2023 | Vraylar, Qulipta, Ubrelvy |
| Exact Sciences Corporation | $140.93 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $139.01 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.25 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $131.66 | 2019-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $131.53 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $62.59 | 2019-2022 | |
| Dexcom, INC. | $62.36 | 2023-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $59.26 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $55.34 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.36 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $43.05 | 2023 | Rexulti |
| Abbott Laboratories | $31.53 | 2021-2022 | |
| Alkermes, INC. | $30.96 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $28.55 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $26.05 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.94 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $20.10 | 2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $19.38 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.85 | 2022 | |
| Corcept Therapeutics | $17.52 | 2019 | |
| Horizon Therapeutics Plc | $17.28 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.66 | 2023 | Qelbree |
| Shield Therapeutics INC | $15.79 | 2023 | Accrufer |
| Lundbeck LLC | $14.29 | 2022 | |
| Mylan Specialty L.P. | $11.80 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelly Bray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.